SEMINAR: Mass spectrometry based bioanalytics for the support of pharmacotherapies in general and oncology studies in particular

Veranstaltung ausschließlich für Fachpublikum

Dear Colleagues,

It is my pleasure to cordially invite you to the upcoming Seminar, which will focus on:

SEMINAR: Mass spectrometry based bioanalytics for the support of pharmacotherapies in general and oncology studies in particular

Speaker:        Dr. Jürgen Burhenne
Universitätsklinikum Heidelberg, Analytisch-Chemisches Labor, Abteilung Klinische Pharmakologie und Pharmakoepidemiologie
 
Date:              7th December, 2018
Time:              14:30 – 15:15 Uhr
Venue:           Charité – Universitätsmedizin | Charité Campus Mitte
Charité Comprehensive Cancer Center | Konferenzraum, Ebene 3, Invalidenstr. 80, 10115 Berlin
 
Abstract:
Mass spectrometry (MS) is an extremely specific and sensitive methodology, which is in use since centuries in chemistry and pharmacy for the structural elucidation of organic compounds. Developments of multiple MS techniques, as well as advanced improvements in the MS coupled chromatography (LC/MS), ionization, and raise of sensitivity led to a revolution in bioanalytics and entrance to biomedical applications. Bioanalytical MS is the state-of-the-art technique for qualitative structural elucidation of unknown biomolecules (proteomics, metabolomics, lipidomics) and for quantitative analysis of endogenic metabolites and exogenic drugs in pharmacotherapy. The latter can be quantified in blood plasma down to the femtomolar region for therapeutic drug monitoring or for pharmacokinetic purposes. More sophisticated, scientific applications are currently the quantitative determinations of drugs at the site of action, since effectivity is only expectable if the drug reaches the receptor/site of action in sufficient concentration. This could be in blood (leukemia, HIV), however, very often these are by barriers (membranes, blood-brain-barrier) protected regions/areas (tissue, organs, tumors, brain tumors) with limited access. Within this talk respective MS techniques and their medical applications will be exemplary presented and discussed together with the additional clinical information given by this technique.
 
All are most warmly invited to attend. Please feel free to circulate this email among colleagues who might be interested. 

We look very much forward to an interesting exchange of thoughts and experience as well as to exciting discussions.

Best regards,

Angelika Eggert
Director Medical Department of Pediatrics,
Division of Oncology and Hematology CVK,
DKTK spokesperson
 
Clemens Schmitt
Director Molecular Research Centre of the Charité (MKFZ)
Director of the Berlin School of Integrative Oncology (BSIO)             

Kontakt